Home Tags Dolaflexin platform

Tag: Dolaflexin platform

U.S. FDA Lifts Partial Clinical Hold for Mersana’s XMT-1522

The United States Food and Drug Administration (FDA) has lifted the partial clinical hold on the Phase I study of XMT-1522, a Dolaflexin® Antibody-drug...

FDA Clears Mersana’s IND Application for XMT-1536

Focusing on discovering and developing a pipeline of novel antibody-drug conjugates or ADCs based on its proprietary Dolaflexin® platform, Mersana Therapeutics' Investigational New Drug...

Preclinical Data Supports the Development of XMT-1536 in a Broad Population...

Update data from preclinical studies with XMT-1536, an antibody-drug conjugates or ADC being developed by Mersana Therapeutics targeting NaPi2b, were presented in a poster...

AACR 2017: New Preclinical Data to be Presented on Mersana’s XMT-1522

Mersana Therapeutics earlier today announced that it will present data on its lead preclinical immunoconjugate, XMT-1522, at the American Association of Cancer Research (AACR)...

XMT-1522 Demonstrates Potent Activity in Low HER2-Expressing Tumor Models

Preclinical data for XMT-1522, a novel HER2-targeting therapy based on Mersana Therapeutics' Dolaflexin platform, the company's most advanced Fleximer® proprietary immunoconjugate technology, demonstrates significant anti-cancer activity...

FEATURED RESOURCES